NLS quretech bio

The company receives support from the Swedish Research Council’s major investment ENABLE-2, which in collaboration with Vinnova gives small and medium-sized companies access to the ENABLE-2 platform to continue development of new antibiotics. QureTech Bio is developing new drugs that either enhance the existing effects of antibiotics or disarm bacteria instead of killing them, thereby […]

QureTech Bio has appointed Helén Fält as its new acting CEO, replacing Fredrik Almqvist, one of the company’s original founders. “We have recently secured significant new investment and so it feels like the perfect time for Helén to come in and develop our business even further,” says Fredrik Almqvist. Venture capital company Nascent Invest recently […]

QureTech Bio has received preliminary approval for a patent application in the US for a drug candidate that helps treat tuberculosis. “The US is a key market for us so this news really helps strengthen our position. We are at a very exciting stage right now,” says Fredrik Almqvist, CEO of QureTech Bio. “We have […]

Fredrik Almqvist, professor in organic chemistry at Umeå University and serial entrepreneur, receives Baltic’s collaboration and entrepreneurship award. He receives the award for successfully combining entrepreneurship with excellent research in chemical production and the combat against pathogenic bacteria. The world is full of problems. Fredrik Almqvist has always been aiming to contribute with new solutions […]

The winner of the Start-up Slam: Sweden, a pitching competition, taking place at BIO-Europe Spring in Stockholm for the first time, was QureTech Bio AB, a start-up developing first line drugs to combat antibiotic resistance and infectious diseases. This session at the event was co-sponsored by Karolinska Institutet Innovations AB and Johnson & Johnson Innovation […]